Journal of Molecular and Cellular Cardiology
Volume 49, Issue 5 , Pages 762-770 , November 2010

Roles of phospho-GSK-3β in myocardial protection afforded by activation of the mitochondrial KATP channel

Received 29 October 2009 ,Revised 26 July 2010 ,Accepted 1 August 2010.

References 

  1. Szewczyk A, Jarmuszkiewicz W, Kunz WS. Mitochondrial potassium channels. IUBMB Life. 2009;61:134–143
  2. Ardehali H, O'Rourke B. Mitochondrial KATP channels in cell survival and death. J Mol Cell Cardiol. 2005;39:7–16
  3. Downey JM, Krieg T, Cohen MV. Mapping preconditioning's signaling pathways: an engineering approach. Ann NY Acad Sci. 2008;1123:187–196
  4. Murphy E, Steenbergen C. Preconditioning: the mitochondrial connection. Annu Rev Physiol. 2007;69:51–67
  5. Penna C, Mancardi D, Rastaldo R, Losano G, Pagliaro P. Intermittent activation of bradykinin B2 receptors and mitochondrial KATP channels trigger cardiac postconditioning through redox signaling. Cardiovasc Res. 2007;75:168–177
  6. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol. 2004;44:1103–1110
  7. Oldenburg O, Qin Q, Krieg T, Yang XM, Philipp S, Critz SD, et al. Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. Am J Physiol Heart Circ Physiol. 2004;286:H468–H476
  8. Andrukhiv A, Costa AD, West IC, Garlid KD. Opening mitoKATP increases superoxide generation from complex I of the electron transport chain. Am J Physiol Heart Circ Physiol. 2006;291:H2067–H2074
  9. Ishida H, Hirota Y, Genka C, Nakazawa H, Nakaya H, Sato T. Opening of mitochondrial KATP channels attenuates the ouabain-induced calcium overload in mitochondria. Circ Res. 2001;89:856–858
  10. Garlid KD, Dos Santos P, Xie ZJ, Costa AD, Paucek P. Mitochondrial potassium transport: the role of the mitochondrial ATP-sensitive K+ channel in cardiac function and cardioprotection. Biochim Biophys Acta. 2003;1606:1–21
  11. Juhaszova M, Zorov DB, Yaniv Y, Nuss HB, Wang S, Sollott SJ. Role of glycogen synthase kinase-3β in cardioprotection. Circ Res. 2009;104:1240–1252
  12. Miura T, Miki T. GSK-3β, a therapeutic target for cardiomyocyte protection. Circ J. 2009;73:1184–1192
  13. Lim KH, Javadov SA, Das M, Clarke SJ, Suleiman MS, Halestrap AP. The effects of ischaemic preconditioning, diazoxide and 5-hydroxydecanoate on rat heart mitochondrial volume and respiration. J Physiol. 2002;545(Pt 3):961–974
  14. Hanley PJ, Mickel M, Löffler M, Brandt U, Daut J. KATP channel-independent targets of diazoxide and 5-hydroxydecanoate in the heart. J Physiol. 2002;542(Pt 3):735–741
  15. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?. Cardiovasc Res. 2002;55:534–543
  16. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest. 2004;113:1535–1549
  17. Nishihara M, Miura T, Miki T, Tanno M, Yano T, Naitoh K, et al. Modulation of the mitochondrial permeability transition pore complex in GSK-3β-mediated myocardial protection. J Mol Cell Cardiol. 2007;43:564–570
  18. Miki T, Yano T, Miura T, Tanno M, Shimamoto K. Enhanced ANT–cyclophilin-D interaction underlies reduced anti-infarct tolerance and loss of protective response to erythropoietin in hypertensive hypertrophied hearts. [Abstract] Eur Heart J. 2009;30(Suppl.1):213
  19. Miki T, Miura T, Yano T, Takahashi A, Sakamoto J, Tanno M, et al. Alteration in erythropoietin-induced cardioprotective signaling by postinfarct ventricular remodeling. J Pharmacol Exp Ther. 2006;317:68–75
  20. Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov. 2004;3:479–487
  21. Jope RS. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trend Pharmacol Sci. 2003;24:441–443
  22. Grover GJ, McCullough JR, D'Alonzo AJ, Sargent CA, Atwal KS. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448. J Cardiovasc Pharmacol. 1995;25:40–50
  23. Schultz JE, Qian YZ, Gross GJ, Kukreja RC. The ischemia-selective KATP channel antagonist, 5-hydroxydecanoate, blocks ischemic preconditioning in the rat heart. J Mol Cell Cardiol. 1997;29:1055–1060
  24. Tanno M, Miura T, Tsuchida A, Miki T, Nishino Y, Ohnuma Y, et al. Contribution of both the sarcolemmal KATP and mitochondrial KATP channels to infarct size limitation by KATP channel openers: differences from preconditioning in the role of sarcolemmal KATP channels. Naunyn Schmiedebergs Arch Pharmacol. 2001;364:226–232
  25. Kobayashi H, Miura T, Ishida H, Miki T, Tanno M, Yano T, et al. Limitation of infarct size by erythropoietin is associated with translocation of Akt to the mitochondria after reperfusion. Clin Exp Pharmacol Physiol. 2008;35:812–819
  26. Dost T, Cohen MV, Downey JM. Redox signaling triggers protection during the reperfusion rather than the ischemic phase of preconditioning. Basic Res Cardiol. 2008;103:378–384
  27. Solenkova NV, Solodushko V, Cohen MV, Downey JM. Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. Am J Physiol Heart Circ Physiol. 2006;290:H441–H449
  28. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol. 2005;288:H971–H976
  29. Philipp S, Yang X-M, Cui L, Davis AM, Downey JM, Cohen MV. Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc Res. 2006;70:308–314
  30. Kuno A, Critz SD, Cui L, Solodushko V, Yang XM, Krahn T, et al. Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007;43:262–271
  31. Zorov DB, Juhaszova M, Yaniv Y, Nuss HB, Wang S, Sollott SJ. Regulation and pharmacology of the mitochondrial permeability transition pore. Cardiovasc Res. 2009;83:213–225
  32. Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, Bernard P. Properties of the permeability transition pore in mitochondria devoid of cyclophilin D. J Biol Chem. 2005;280:18558–18561
  33. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature. 2005;434:658–662
  34. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 2005;434:652–658
  35. Argaud L, Gateau-Roesch O, Muntean D, Chalabreysse L, Loufouat J, Robert D, et al. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol. 2005;38:367–374
  36. Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem. 2003;278:33067–33077
  37. Giorgio V, Bisetto E, Soriano ME, Dabbeni-Sala F, Basso E, Petronilli V, et al. Cyclophilin D modulates mitochondrial F0F1-ATP synthase by interacting with the lateral stalk of the complex. J Biol Chem. 2009;284:33982–33988
  38. Jennings RB, Reimer KA. The cell biology of acute myocardial ischemia. Annu Rev Med. 1991;42:225–246
  39. Murry CE, Richard VJ, Reimer KA, Jennings RB. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res. 1990;66:913–931
  40. Schwartz LM, Reimer KA, Crago MS, Jennings RB. Pharmacological preconditioning with diazoxide slows energy metabolism during sustained ischemia. Exp Clin Cardiol. 2007;12:139–147
  41. Das S, Wong R, Rajapakse N, Murphy E, Steenbergen C. Glycogen synthase kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates voltage-dependent anion channel phosphorylation. Circ Res. 2008;103:983–991
  42. McCarthy J, McLeod CJ, Minners J, Essop MF, Ping P, Sack MN. PKCε activation augments cardiac mitochondrial respiratory post-anoxic reserve — a putative mechanism in PKCε cardioprotection. J Mol Cell Cardiol. 2005;38:697–700
  43. Ko YH, Delannoy M, Hullihen J, Chiu W, Pedersen PL. Mitochondrial ATP synthasome. Cristae-enriched membranes and a multiwell detergent screening assay yield dispersed single complexes containing the ATP synthase and carriers for Pi and ADP/ATP. J Biol Chem. 2003;278:12305–12309
  44. Chen C, Ko Y, Delannoy M, Ludtke SJ, Chiu W, Pedersen PL. Mitochondrial ATP synthasome: three-dimensional structure by electron microscopy of the ATP synthase in complex formation with carriers for Pi and ADP/ATP. J Biol Chem. 2004;279:31761–31768

PII: S0022-2828(10)00285-3

doi: 10.1016/j.yjmcc.2010.08.001

Journal of Molecular and Cellular Cardiology
Volume 49, Issue 5 , Pages 762-770 , November 2010

Article Tools

* Image Usage & Resolution